STP-705 is under clinical development by Sirnaomics and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect STP-705’s likelihood of approval (LoA) and phase transition for Basal Cell Carcinoma (Basal Cell Epithelioma) took place on 25 Jul 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
In addition, the same event on 25 Jul 2022 increased STP-705’s LoA and PTSR for Squamous Cell Carcinoma.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their STP-705 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
STP705 is under development for the treatment of cutaneous squamous cell carcinoma in situ (isSCC, Bowen's disease), facial squamous cell skin cancer in situ (isSCC), advanced liver tumor, pancreatic cancer, hepatocellular cancer, bladder cancer, basal cell carcinoma, primary sclerosing cholangitis, keloid scarless healing, skin hypertrophic scars, non-alcoholic steatohepatitis, abdominal obesity, cholangiocarcinoma and liver metastasis. The drug is administered topically as cream, through intradermal injection and intra-tumorally and subcutaneously. It is developed based on RNAi technology. It was under development for the treatment of pulmonary fibrosis,kidney fibrosis and wounds.
Sirnaomics, is a healthcare service provider that discovers and develops therapeutics. The company’s products portfolio includes siRNA and niRNA. It offers product development, preclinical programs, clinical development services, and others. Sirnaomics provides its products for therapeutic programs such as lung cancer, breast cancer, organ transplantation, skin hypertrophic scars, colorectal cancer, influenza A, HPV and cervical cancer, ocular neo-vascularization, spinal cord injury, EBOLA infection, and giloblastoma, among others. The company also provides active pharmaceutical ingredients as therapeutic agents for treatment of various critical human diseases. It has its presence in the US and China. the company is headquartered in Gaithersburg, Maryland, the US.
Quick View STP-705 LOA Data
|Highest Development Stage|